138 related articles for article (PubMed ID: 12185560)
1. Modeling of human hepatic CYP3A4 enzyme kinetics, protein, and mRNA indicates deviation from log-normal distribution in CYP3A4 gene expression.
Sy SK; Ciaccia A; Li W; Roberts EA; Okey A; Kalow W; Tang BK
Eur J Clin Pharmacol; 2002 Aug; 58(5):357-65. PubMed ID: 12185560
[TBL] [Abstract][Full Text] [Related]
2. Limited contribution of CYP3A5 to the hepatic 6beta-hydroxylation of testosterone.
Kamdem LK; Meineke I; Koch I; Zanger UM; Brockmöller J; Wojnowski L
Naunyn Schmiedebergs Arch Pharmacol; 2004 Jul; 370(1):71-7. PubMed ID: 15232676
[TBL] [Abstract][Full Text] [Related]
3. CYP3A5 Contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects.
Yamaori S; Yamazaki H; Iwano S; Kiyotani K; Matsumura K; Honda G; Nakagawa K; Ishizaki T; Kamataki T
Drug Metab Pharmacokinet; 2004 Apr; 19(2):120-9. PubMed ID: 15499178
[TBL] [Abstract][Full Text] [Related]
4. Role of a potent inhibitory monoclonal antibody to cytochrome P-450 3A4 in assessment of human drug metabolism.
Mei Q; Tang C; Assang C; Lin Y; Slaughter D; Rodrigues AD; Baillie TA; Rushmore TH; Shou M
J Pharmacol Exp Ther; 1999 Nov; 291(2):749-59. PubMed ID: 10525096
[TBL] [Abstract][Full Text] [Related]
5. Expression of CYP3A4 mRNA is correlated with CYP3A4 protein level and metabolic activity in human liver.
Watanabe M; Kumai T; Matsumoto N; Tanaka M; Suzuki S; Satoh T; Kobayashi S
J Pharmacol Sci; 2004 Apr; 94(4):459-62. PubMed ID: 15107587
[TBL] [Abstract][Full Text] [Related]
6. Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5'-upstream regulatory region.
Westlind A; Löfberg L; Tindberg N; Andersson TB; Ingelman-Sundberg M
Biochem Biophys Res Commun; 1999 May; 259(1):201-5. PubMed ID: 10334940
[TBL] [Abstract][Full Text] [Related]
7. Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor.
Tang C; Shou M; Mei Q; Rushmore TH; Rodrigues AD
J Pharmacol Exp Ther; 2000 May; 293(2):453-9. PubMed ID: 10773015
[TBL] [Abstract][Full Text] [Related]
8. Factors influencing midazolam hydroxylation activity in human liver microsomes.
He P; Court MH; Greenblatt DJ; von Moltke LL
Drug Metab Dispos; 2006 Jul; 34(7):1198-207. PubMed ID: 16638818
[TBL] [Abstract][Full Text] [Related]
9. Kinetics of testosterone 6beta-hydroxylation in the reconstituted system with similar ratios of purified CYP3A4, NADPH-cytochrome p450 oxidoreductase and cytochrome B5 to human liver microsomes.
Taguchi M; Imaoka S; Yoshii K; Kobayashi K; Hosokawa M; Shimada N; Funae Y; Chiba K
Res Commun Mol Pathol Pharmacol; 2001 Jul; 109(1-2):53-63. PubMed ID: 11458985
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of cytochrome P-450 3A4 catalytic activities by cytochrome b(5) in bacterial membranes.
Yamazaki H; Nakajima M; Nakamura M; Asahi S; Shimada N; Gillam EM; Guengerich FP; Shimada T; Yokoi T
Drug Metab Dispos; 1999 Sep; 27(9):999-1004. PubMed ID: 10460798
[TBL] [Abstract][Full Text] [Related]
11. MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype.
Lamba J; Strom S; Venkataramanan R; Thummel KE; Lin YS; Liu W; Cheng C; Lamba V; Watkins PB; Schuetz E
Clin Pharmacol Ther; 2006 Apr; 79(4):325-38. PubMed ID: 16580901
[TBL] [Abstract][Full Text] [Related]
12. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation.
Butler AM; Murray M
J Pharmacol Exp Ther; 1997 Feb; 280(2):966-73. PubMed ID: 9023313
[TBL] [Abstract][Full Text] [Related]
13. Relationship between mRNA levels quantified by reverse transcription-competitive PCR and metabolic activity of CYP3A4 and CYP2E1 in human liver.
Sumida A; Kinoshita K; Fukuda T; Matsuda H; Yamamoto I; Inaba T; Azuma J
Biochem Biophys Res Commun; 1999 Aug; 262(2):499-503. PubMed ID: 10462503
[TBL] [Abstract][Full Text] [Related]
14. Coexpression of genetically engineered fused enzyme between yeast NADPH-P450 reductase and human cytochrome P450 3A4 and human cytochrome b5 in yeast.
Hayashi K; Sakaki T; Kominami S; Inouye K; Yabusaki Y
Arch Biochem Biophys; 2000 Sep; 381(1):164-70. PubMed ID: 11019832
[TBL] [Abstract][Full Text] [Related]
15. A literature review of enzyme kinetic parameters for CYP3A4-mediated metabolic reactions of 113 drugs in human liver microsomes: structure-kinetics relationship assessment.
Bu HZ
Curr Drug Metab; 2006 Apr; 7(3):231-49. PubMed ID: 16611019
[TBL] [Abstract][Full Text] [Related]
16. Metabolic characterization of the major human small intestinal cytochrome p450s.
Obach RS; Zhang QY; Dunbar D; Kaminsky LS
Drug Metab Dispos; 2001 Mar; 29(3):347-52. PubMed ID: 11181505
[TBL] [Abstract][Full Text] [Related]
17. Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism.
Westlind-Johnsson A; Malmebo S; Johansson A; Otter C; Andersson TB; Johansson I; Edwards RJ; Boobis AR; Ingelman-Sundberg M
Drug Metab Dispos; 2003 Jun; 31(6):755-61. PubMed ID: 12756208
[TBL] [Abstract][Full Text] [Related]
18. Cytochrome P450 3A4-catalyzed testosterone 6beta-hydroxylation stereochemistry, kinetic deuterium isotope effects, and rate-limiting steps.
Krauser JA; Guengerich FP
J Biol Chem; 2005 May; 280(20):19496-506. PubMed ID: 15772082
[TBL] [Abstract][Full Text] [Related]
19. Variability of CYP3A7 expression in human fetal liver.
Leeder JS; Gaedigk R; Marcucci KA; Gaedigk A; Vyhlidal CA; Schindel BP; Pearce RE
J Pharmacol Exp Ther; 2005 Aug; 314(2):626-35. PubMed ID: 15845858
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the contribution of cytochrome P450 3A4 to human liver microsomal bupropion hydroxylation.
Faucette SR; Hawke RL; Shord SS; Lecluyse EL; Lindley CM
Drug Metab Dispos; 2001 Aug; 29(8):1123-9. PubMed ID: 11454731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
